Short interest in Inhibikase Therapeutics Inc (NASDAQ:IKT) decreased during the last reporting period, falling from 305.66K to 287.66K. This put 0.54% of the company's publicly available shares short.

Short interest for Inhibikase Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Inhibikase Therapeutics's stock. Short interest data is updated every two weeks.

Based on the recent average volume of 181.13K shares traded per day, it would take 1.59 day(s) for holders of this short interest to close out their positions without sending the stock sharply higher.